New insider activity at Relay Therapeutics ( (RLAY) ) has taken place on April 25, 2025.
President and CEO Sanjiv Patel recently sold 61,422 shares of Relay Therapeutics stock, amounting to a total transaction value of $182,423.
Recent Updates on RLAY stock
In the past 24 hours, Relay Therapeutics has seen mixed analyst opinions regarding its stock. Wells Fargo initiated coverage with an Equal Weight rating, citing the potential of its lead program RLY-2608 but expressing concerns over a lack of near-term catalysts, which could limit upside potential despite the stock’s current low price. Conversely, Barclays sees the recent pullback in Relay’s shares as a buying opportunity, highlighting the company’s significant upside potential due to its exposure to AI-driven drug discovery and a strong cash position that extends into the second half of 2027. Barclays maintains an Overweight rating, emphasizing the favorable risk/reward profile. Meanwhile, Citizens JMP lowered its price target for Relay from $21 to $12, reflecting adjustments in market expectations. Overall, the stock’s movements are influenced by differing views on its strategic positioning, financial stability, and clinical trial progress.
Spark’s Take on RLAY Stock
According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.
Relay Therapeutics exhibits significant challenges, with ongoing losses and negative cash flow impacting its financial performance. Technical analysis suggests a bearish trend, and valuation metrics are unfavorable due to the absence of positive earnings and dividend yield. These factors contribute to a below-average stock score, reflecting the company’s current financial and market position.
To see Spark’s full report on RLAY stock, click here.
More about Relay Therapeutics
YTD Price Performance: -27.67%
Average Trading Volume: 2,323,363
Technical Sentiment Signal: Buy
Current Market Cap: $496.7M